Linda Lebon
Algemeen Adviseur bij OSE IMMUNOTHERAPEUTICS
Profiel
Linda Lebon is currently the Chief Regulatory Officer at OSE Immunotherapeutics SA since 2021.
Prior to this, she worked as the Chief Regulatory Officer at Bone Therapeutics SA from 2018 to 2021.
Before that, she held the position of Vice President-Regulatory Affairs at argenx SE and Director-Regulatory Affairs at iTeos Therapeutics SA. Ms. Lebon holds an MBA from École des Hautes Études Commerciales de Paris and a graduate degree from Centre Hospitalier Universitaire de Liege.
Actieve functies van Linda Lebon
| Bedrijven | Functie | Begin |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Algemeen Adviseur | 20-12-2021 |
Eerdere bekende functies van Linda Lebon
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOSENIC SA | Algemeen Adviseur | 01-09-2021 |
| ARGENX SE | Algemeen Adviseur | - |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Algemeen Adviseur | - |
Opleiding van Linda Lebon
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
| Centre Hospitalier Universitaire de Liege | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ARGENX SE | Health Technology |
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Bone Therapeutics SA
 Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Bone Therapeutics SA is a cell therapy company, which engages in the regenerative therapy addressing for unmet medical needs in the field of bone diseases and orthopedics. Its products include Allob and JTA-004. The company was founded by Jacques Reymann on June 16, 2006 and is headquartered in Gosselies, Belgium. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
